Legend Biotech (LEGN) Net Income towards Common Stockholders Growth (3y) (2022 - 2026)

Legend Biotech (LEGN) Net Income towards Common Stockholders Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.30%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 10.23%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 71.02%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 37.89%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 25.99%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -38.56%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 37.44%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 62.15%
10 Legend Biotech 3.95 Bn 3.27 Bn 251.50 Mn -57.20%

Historic Data

Download Data
DateValue
Jun 30, 2026 -57.20%
Mar 31, 2026 21.13%
Dec 31, 2025 38.96%
Sep 30, 2025 23.22%
Jun 30, 2025 13.70%
Mar 31, 2025 -46.21%
Dec 31, 2024 12.55%
Sep 30, 2024 -0.15%
Jun 30, 2024 -28.17%
Mar 31, 2024 -770.90%
Dec 31, 2023 -15.26%
Sep 30, 2023 2.22%
Jun 30, 2023 -13.87%
Mar 31, 2023 -36.34%
Dec 31, 2022 -28.56%
Sep 30, 2022 -45.12%
Jun 30, 2022 -88.60%